Oncogenic Function of DACT1 in Colon Cancer through the Regulation of β-catenin by Yuan, Guohong et al.
Oncogenic Function of DACT1 in Colon Cancer through
the Regulation of b-catenin
Guohong Yuan, Chongkai Wang, Chaolai Ma, Ning Chen, Qinghe Tian, Tonglin Zhang, Wei Fu*
Department of General Surgery, Peking University Third Hospital, Beijing, China
Abstract
The Wnt/b-catenin signaling pathway plays important roles in the progression of colon cancer. DACT1 has been identified as
a modulator of Wnt signaling through its interaction with Dishevelled (Dvl), a central mediator of both the canonical and
noncanonical Wnt pathways. However, the functions of DACT1 in the WNT/b-catenin signaling pathway remain unclear.
Here, we present evidence that DACT1 is an important positive regulator in colon cancer through regulating the stability
and sublocation of b-catenin. We have shown that DACT1 promotes cancer cell proliferation in vitro and tumor growth in
vivo and enhances the migratory and invasive potential of colon cancer cells. Furthermore, the higher expression of DACT1
not only increases the nuclear and cytoplasmic fractions of b-catenin, but also increases its membrane-associated fraction.
The overexpression of DACT1 leads to the increased accumulation of nonphosphorylated b-catenin in the cytoplasm and
particularly in the nuclei. We have demonstrated that DACT1 interacts with GSK-3b and b-catenin. DACT1 stabilizes b-catenin
via DACT1-induced effects on GSK-3b and directly interacts with b-catenin proteins. The level of phosphorylated GSK-3b at
Ser9 is significantly increased following the elevated expression of DACT1. DACT1 mediates the subcellular localization of b-
catenin via increasing the level of phosphorylated GSK-3b at Ser9 to inhibit the activity of GSK-3b. Taken together, our study
identifies DACT1 as an important positive regulator in colon cancer and suggests a potential strategy for the therapeutic
control of the b-catenin-dependent pathway.
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Introduction
Mutations and the dysregulated expression of components of
the ancient Wnt signaling pathway are linked to oncogenesis in
multiple systems, and have been particularly implicated in the
initiation of colon cancer [1,2,3,4,5,6,7,8]. Over 90% of colorectal
cancers originate from active mutations in the Wnt pathway [1].
Mutations have been described in the adenomatous polyposis coli
(APC) gene in cases of familial adenomatous polyposis (FAP), and
this mutation also occurs in a high proportion of sporadic
colorectal cancers [9,10]. APC mutations represent an early event
in colorectal tumorigenesis [11].
b-catenin (official symbol CTNB1) is considered to be a central
player in the Wnt signaling pathway. Although Wnt activation can
occur through mutations that affect phosphorylation sites within
exon 3 of b-catenin in a minority of colorectal tumors [12,13],
many other components of the Wnt signaling pathway contribute
to colorectal cancer via dysregulating the activity or localization of
b-catenin [14,15].
The DACT1 (Dapper1/Dpr1) gene, located at chromosome
14q22.3, encodes a 836 amino acid protein with a putative leucine
zipper (LZ) domain in the amino-terminal end and a consensus
PDZ binding (PDZ-B) motif in the carboxy-terminal end that
allows the DACT1 protein to interact with the Dishevelled (Dvl)
PDZ domain [16]. Bioinformatic analyses have revealed that
DACT1 mRNA is expressed in the amnion, fetal brain, eye, heart,
adult brain medulla, gastric cancer (signet ring cell features),
RER+ colon tumor, acute lymphoblastic leukemia, germ cell
tumor, chondrosarcoma, and parathyroid tumors [17]. Further-
more, based on the evolutionary and functional conservation of
Wnt signaling molecules, as well as the human chromosomal
localization of DACT1, the DACT1 gene is also predicted to be a
potent cancer-associated gene [17]. DACT1 has been reported to
be downregulated in hepatocellular carcinoma [18]. A recent
report identified a correlation between DACT1 expression in lung
cancer and poor histological grade, large tumor size, extent of
tumor invasion, and lymph node metastasis [19].
Although some studies have shown associations between DACT1
expression and cancer, the function of DACT1 in the WNT/b-
catenin signaling pathway remains unclear. One possible mech-
anism is that Dpr stabilizes GSK-3b and axin in the APC
complex, as shown by co-immunoprecipitation studies [16].
Another possibility is that Dpr competes with Fz for binding to
the PDZ domain of Dvl, thereby blocking the signal transduction
via Dvl, and hence inhibits the Dvl-mediated stabilization of b-
catenin [20]. Yau et al. reported that human Dpr1 was
downregulated in hepatocellular carcinoma, and this downregu-
lation was correlated with the cytoplasmic accumulation of b-
catenin [18]. However, in this report, we have found that DACT1
is overexpressed in colon cancer, and it acts to enhance cellular
proliferation, migration and invasion in colon cancer cell lines. We
have shown that DACT1 interacts with GSK-3b and b-catenin.
We have further demonstrated that DACT1 stabilizes b-catenin via
DACT1-induced effects on GSK-3b and directly interacts with b-
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GSK-3b via increasing the level of phosphorylated GSK-3b at
Ser9, which alters the subcellular location of b-catenin. It
particularly promotes b-catenin levels at the plasma membrane
and in the nucleus.
Results
DACT1 is overexpressed in human colon carcinoma
To identify the potential roles of DACT1 in the development
and progression of colonic carcinoma, we used quantitative real-
time PCR (qRT-PCR) to assess the level of gene expression. We
compared the expression in six cancer tissues to those in six paired
samples of normal control colonic mucosa. The results showed
that the level of DACT1 mRNA was significantly elevated in all six
samples of colon cancer (Figure 1A). The gene expression data
were further confirmed by Western blotting, which were
performed with the use of soluble cell lysates prepared from
surgical colectomy specimens. The results confirmed that high
levels of DACT1 protein are present in colon cancer (Figure 1B).
DACT1 enhances cellular proliferation in vitro and colon
tumorigenesis in vivo
To understand the function of DACT1 in colon cancer, we
explored the effect of ectopic DACT1 expression on cellular growth
in vitro in cell lines with different levels of endogenous DACT1
expression. Following transfection with a DACT1 cDNA expres-
sion construct, SW480 colon cancer cells, which express very low
endogenous levels of DACT1, demonstrated a significant increase
in cellular proliferation (Figure 2A). Conversely, cellular prolifer-
ation decreased when endogenous DACT1 expression was silenced
by stable transfection with siRNA vectors that targeted DACT1 in
the HCT116, LoVo and HT29 colon cancer cell lines, which have
much higher endogenous levels of DACT1 (Figure 2B–D). To
confirm these results, endogenous DACT1 expression was silenced
by stable transfection with another siRNA vectors (DACT1
siRNA1) that targeted distinct regions of DACT1 in the HCT116
cells and the same results were observed (Figure S1A–B).
To examine the effects of the silencing of DACT1 on colon tumor
growth in vivo, HCT116 cells that stably expressed a control siRNA
or DACT1 siRNA were used. Cells (5610
6) were injected into the
subcutaneous tissue of the nude mouse (n=8 animals per group).
Tumors were measured weekly with a vernier caliper, and their
volumes were calculated according to the following formula: p/
66length6width
2 [21]. All of the animals injected with HCT116
cells that expressed control siRNA developed tumors by 14 days
after injection, while only 75% (6/8) of the DACT1 siRNA animals
developed tumors. Fifty-six days after injection, the tumors of the
control siRNA animals were significantly larger (Figure 2F). The
mean tumor volume was 2,068.786561.57 mm
3 in mice injected
with HCT116 cells that expressed control siRNA, compared to the
mean tumor volume in mice injected with HCT116 cells that
expressed DACT1 siRNA (503.466178.90 mm
3) (Figure 2E). These
data demonstrate the important role of DACT1 in promoting the
growth of colon cancer cells.
DACT1 enhances the migration and lack of anchorage of
colon cancer cells
Anchorage-independent proliferation is a hallmark of oncogenic
transformation and is regarded to be conducive to the proliferation
Figure 1. DACT1 is highly expressed in human colon cancer cells. (A) DACT1 mRNA levels were assayed using quantitative real-time RT-PCR
analysis. Samples of colon adenocarcinoma (T, white bars) and normal-appearing control mucosa (N, black bars) were analyzed in six cases of colon
cancer. (B) Expression of DACT1 protein in human colon adenocarcinoma (T) and normal-appearing control mucosa (N) in six cases, as determined by
Western immunoblotting analysis. The expression of GAPDH was used as the loading control.
doi:10.1371/journal.pone.0034004.g001
Role of DACT1 in Colon Cancer
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34004Role of DACT1 in Colon Cancer
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34004of cancer cells away from their original site. With this knowledge,
we examined the capacity of DACT1 to drive the anchorage-
independent growth of colon cancer cells by soft agar colony
formation assays. The overexpression of DACT1 enhanced the
anchorage-independent proliferation of SW480 cells (Figure 3A).
Downregulation of DACT1 reduced the anchorage-independent
potential of HCT116, LoVo and HT29 cells (Figure 3B–D and
S1C). Furthermore, we observed that DACT1 overexpression
enhanced the migratory potential of SW480 cells by transwell
assays (Figure 3E and I). Conversely, the migratory potential of
cells was decreased when endogenous DACT1 expression was
silenced by stable transfection with siRNA vectors that targeted
DACT1 in HCT116, LoVo and HT29 cells (Figure 3F–I).
Following these results, we conclude that DACT1 enhances
anchorage independence in colon cancer cells and their migratory
potential.
DACT1 enhances invasion of colon cancer cells in vitro or
in vivo
The most dangerous feature of malignancy is the invasive and
metastatic potential of tumor cells. To test whether cell invasion
was affected by DACT1, the effects of DACT1 on cell invasion
through Matrigel was investigated. Overexpression of DACT1
enhanced the invasion of SW480 cells (Figure 4A and E).
Downregulation of DACT1 reduced the invasive potential of
HCT116, LoVo and HT29 cells through the Matrigel (Figure 4B–
E). To examine the effects of DACT1 silencing on the invasion of
colon cancer cells in vivo, we infected HCT116 cells that
expressed a control siRNA or DACT1 siRNA. Then, 5610
6 cells
were injected into the subcutaneous tissue of each nude mouse
(n=8 animals per group). Fifty-six days later, the tumors of six out
of eight control siRNA-transfected nude mice had invaded into the
musculature, while only two of the tumors in DACT1 siRNA-
transfected animals had invaded into the musculature. These data
further show that DACT1 did affect the invasive potential of colon
cancer cells in vitro and in vivo.
DACT1 regulates the cell cycle though increasing b-
catenin levels
To elucidate the mechanism which caused the above results
further, we tested the protein levels of the b-catenin and the Wnt/
b-catenin target genes, cyclin D1 [8] and c-Myc [22]. Our
experiment showed that overexpression of DACT1 resulted in a
significant increase in the total levels of b-catenin, cyclin D1 and c-
Myc in SW480 cells (Figure 5A). Conversely, DACT1 siRNA,
which mediated the silencing of endogenous DACT1 expression,
decreased the total levels of b-catenin, cyclin D1 and c-Myc levels
in HCT116, LoVo and HT29 cells (Figure 5B).
Considering that cyclin D1 and c-Myc are related to cell cycle
regulation, we examined the effect of DACT1 overexpression and
silencing on cell cycle regulation in colon cancer cells. In these
experiments, all of the cells were synchronized at the G0/G1
phases by serum starvation. Cell cycle profiling by FACS indicated
that the overexpression of DACT1 in SW480 cells was associated
with an increase in the proportion of cells in the G0/G1 phases
(Figure 5C). Consistently, silencing of DACT1 expression with
siRNA resulted in an increased number of cells in the S+G2/M
phases in the HCT116, LoVo and HT29 cell lines (Figure 5D–F).
These results suggest that the S+G2/M accumulation of cells after
DACT1 silencing is specifically associated with the loss of DACT1
protein. Collectively, these results indicate that DACT1 promotes
the proliferation of colon cancer cells by facilitating the transition
from the G1 to the S phase of the cell cycle.
Besides cyclin D1, CDK4 is another key factor that facilitates
the G1/S transition. We noted that the overexpression of DACT1
in SW480 cells increased the expression of CDK4, while CDK4
levels were significantly reduced in HCT116, LoVo and HT29
cells that expressed DACT1 siRNA (Figure S2). Together, these
results clearly show that DACT1 stimulates cell proliferation and
tumor growth by promoting the entry of cells into the cell cycle
through increasing levels of b-catenin.
DACT 1 enhances migratory and invasive potential of
colon cancer cells through changing the subcellular
location of b-catenin
To reveal the means by which DACT1 increases b-catenin/
TCF-regulated gene expression, the precise location of b-catenin
was observed under a laser scanning confocal microscope (LSCM)
by immunofluorescence. The results showed that the higher
expression of DACT1 not only increased the nuclear and
cytoplasmic fractions of b-catenin, but also increased its mem-
brane-associated fraction. The change in the level of the b-catenin
membrane-associated fraction was the most significant finding
(Figure 6A–D and S1D).
To confirm these interesting results, extracts from control/
DACT1-overexpressing SW480 cells and control/DACT1-silenced
HCT116 cells were separated into membrane, cytoplasmic, and
nuclear fractions. Then, the relative abundance of b-catenin in
these fractions was analyzed by Western blotting (Figure 6E and
F). Previous reports have demonstrated an important role for b-
catenin in cell adhesion as a part of a protein complex that
includes E-cadherin [23]. The E-cadherin expression pattern in
colon cancer cells was unaltered by DACT1 silencing or
overexpression (Figure S3). These data suggest that increased
levels of DACT1 affect b-catenin levels and b-catenin/TCF-
dependent transcription by the activation of the Wnt signaling
pathway. They also suggest the possibility that DACT1 enhances
the migratory and invasive potential of colon cancer cells via b-
catenin-mediated stabilization of the adherens junction.
Correlation between DACT1 and membrane-associated
b-catenin expression in vitro and in vivo
From the results of the above experiments, we found that
DACT1 was highly expressed in human colon cancers and that it
promoted the cell growth, migration and invasion potential of
colon cancer cells through its effects on b-catenin signaling. Based
on these findings, we hypothesized that DACT1 and the expression
levels of membrane-associated b-catenin would be positively
correlated in colon cancer cell lines and primary colon cancers.
As shown in Figure 7A and B, the levels of DACT1 and b-catenin
in colon cancer cell lines were correlated. The highest levels of b-
catenin at the cell membrane were observed in HCT116 cells with
Figure 2. DACT1 enhances cellular proliferation and colon tumorigenesis. (A) Left: overexpression of DACT1 in stably transfected SW480
cells. Right: growth curve proliferation assay in DACT1-transfected SW480 cells (mean 6 SEM; n=3, *p,0.05 versus empty vector-transfected cells). (B,
C, D) Left: DACT1 expression in wild-type, control siRNA-transfected, and DACT1 siRNA-transfected HCT116, LoVo and HT29 cells. Right: growth curve
assays in DACT1 siRNA-transfected HCT116, LoVo and HT29 cells (mean 6 SEM; n=3, *p,0.05 versus wild-type cells). (E) Average tumor volume
assessed weekly after the injection of animals with control siRNA-or DACT1 siRNA-transfected HCT116 cells (mean 6 SEM; n=3, *p,0.05). (F)
Representative pictures eight weeks after injection of mouse colon cancer cells with control siRNA or DACT1 siRNA-transfected HCT116 cells.
doi:10.1371/journal.pone.0034004.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34004Figure 3. DACT1 enhances anchorage independence and the migratory potential of colon cancer cells. (A) Soft agar assay in DACT1-
transfected SW480 cells after 14 days of incubation. (B, C, D) Soft agar assay in siRNA-transfected HCT116, LoVo and HT29 cells after 14 days of
incubation. (E) Representative images are shown for the overexpression of DACT1 in stably transfected SW480 cells. Cells were seeded in a transwell
chamber and allowed to migrate across the chamber toward cell-specific conditioned medium for 24 h. Photomicrographs of stained migrating cells
were taken under brightfield illumination (206). (F, G, H) Representative images are shown for DACT1 siRNA-transfected HCT116, LoVo and HT29 cells.
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at the cell membrane and DACT1 proteins were found in HT29
cells. Both membrane-associated b-catenin and DACT1 were
minimally expressed in SW480 cells.
To study the relationship between DACT1 and membrane-
associated b-catenin expression in colon cancer further, immuno-
histochemical and immunofluorescence analyses were performed
of b-catenin in human colon normal and adenocarcinoma tissues
(the six above-mentioned cases). We observed focal staining of
membrane-associated b-catenin in all six tumors (100%;
Figure 7C–H). These results correlate well with the previous
results with regards to b-catenin expression in colon cancer cell
Cells were seeded in a transwell chamber and allowed to migrate across the chamber toward cell-specific conditioned medium for 24 h.
Photomicrographs of stained migrating cells were taken under brightfield illumination (206). (I) Quantification of migration assay. Results were
obtained from three separate experiments each performed in triplicate. Migration was determined by counting cells in six random microscopic fields
per well (mean 6 SEM; *p,0.05 versus control group cells).
doi:10.1371/journal.pone.0034004.g003
Figure 4. DACT1 enhances invasion of colon cancer cells in vitro or in vivo. (A) Representative images are shown for the overexpression of
DACT1-transfected SW480 cells. Cells were seeded in an invasive chamber and allowed to invade the chamber toward cell-specific conditioned
medium for 24 h. Photomicrographs of stained invading cells were taken under brightfield illumination (206). (B, C, D) Representative images are
shown for DACT1 siRNA-transfected HCT116, LoVo and HT29 cells. Cells were seeded in an invasion chamber and allowed to invade the chamber
toward cell-specific conditioned medium for 24 h. Photomicrographs of the stained invading cells were taken under brightfield illumination (206). (E)
Quantification of the migration assay. Results were obtained from three separate experiments each performed in triplicate. Invasion was determined
by counting cells in six random microscopic fields per well (mean 6 SEM; *p,0.05 versus control group cells).
doi:10.1371/journal.pone.0034004.g004
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associated b-catenin may be dependent on the elevated expression
of DACT1.
DACT1 interacts with b-catenin and the components of
the b-catenin destruction complex to stabilize b-catenin
We were interested in clarifying the mechanism by which
elevated levels of DACT1 resulted in increased b-catenin
expression. In the absence of Wnt ligands, cytoplasmic levels of
b-catenin are regulated by the destruction complex that contains
axin, APC, and glycogen synthase kinase-3b (GSK-3b), where b-
catenin is phosphorylated by GSK-3b at multiple serine and
threonine residues in its N terminus. Phosphorylated b-catenin is
then ubiquitinated, leading to its rapid proteasomal degradation
[4,24,25,26,27,28]. To determine whether DACT1 increases b-
catenin levels by influencing b-catenin stability, HCT116 cells
(with or without DACT1 silencing) were incubated with 10 mg/ml
cycloheximide (CHX) to prevent new b-catenin synthesis. Then,
b-catenin levels were measured by Western blotting to reflect the
rate of b-catenin protein degradation. Silencing of DACT1
expression significantly increased the b-catenin degradation rate,
resulting in an evident reduction in the levels of remaining b-
catenin (Figure 8A). This effect of DACT1 on b-catenin stability
was confirmed by an immunofluorescence assay. We found that b-
catenin was degraded more rapidly in HCT116 cells that
expressed DACT1 siRNA than in HCT116 cells expressing control
DACT1 siRNA (Figure 8B).
To ascertain the mechanism by which DACT1 influences b-
catenin stability, we examined whether or not DACT1 interacts
with the components of the multiprotein complex that regulates b-
catenin stability. Our co-immunoprecipitation analysis revealed
colocalization of DACT1 and GSK-3b, DACT1 and axin in SW480
cells stably transfected with a GFP-tagged DACT1 construct
(Figure 8C). Moreover, DACT1 did interact with b-catenin in
Figure 5. DACT1 regulates the cell cycle through increasing levels of b-catenin. (A) Representative Western blots of empty vector-
transfected and DACT1-transfected SW480 cells. Overexpression of DACT1 results in the upregulation of b-catenin and the T cell factor (TCF) target
genes, cyclin D1 and c-Myc. GAPDH was used as the loading control. (B) Representative Western blots of HCT116 and LoVo and HT29 cells expressing
control siRNA or DACT1 siRNA. Silencing of DACT1 expression in HCT116 and LoVo and HT29 cells decreased levels of total b-catenin, cyclin D1 and c-
Myc. GAPDH was used as the loading control. (C) The effect of DACT1 overexpression on the cell cycle profile of SW480 cells. Three days after serum
starvation, cells were analyzed for their cell cycle profile by FACS. The percentage of cells in the G1, G2 and S phases are shown. (D, E, F) The effect of
DACT1 siRNA transfection on the cell cycle profile of HCT116, LoVo and HT29 cells. Three days after serum starvation, cells were analyzed for their cell
cycle profile by FACS. The percentage of cells in the G1, G2 and S phases are shown.
doi:10.1371/journal.pone.0034004.g005
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34004Figure 6. DACT1 enhances the migratory and invasive potential of colon cancer cells through changing the subcellular location of b-
catenin. (A) Photomicrographs of empty vector and DACT1-overexpressing SW480 cells immunostained with an anti-b-catenin antibody (red). (B, C,
D) Photomicrographs of control siRNA and DACT1 siRNA in HCT116, LoVo and HT29 cells immunostained with an anti-b-catenin antibody (red). (E)
Representative blots of b-catenin levels in membrane (Mem), nuclear (Nuc), and cytoplasmic (Cyto) fractions and total lysates (Lys) in SW480 cells.
Laminin B (nuclear expression) and GAPDH (cytoplasmic expression) were used as the loading controls. ‘‘+’’ represents the overexpression DACT1.‘ ‘ 2’’
is empty vector. (F) Representative blots of b-catenin levels in membrane (Mem), nuclear (Nuc), and cytoplasmic (Cyto) fractions and total lysates (Lys)
in HCT116 cells. Laminin B (nuclear expression) and GAPDH (cytoplasmic expression) were used as the loading controls. ‘‘+’’ represents control siRNA.
‘‘2’’ is DACT1 siRNA.
doi:10.1371/journal.pone.0034004.g006
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examined the colocalization of DACT1 with GSK-3b, and DACT1
with b-catenin in wild type HT29 cells (without APC or b-catenin
mutations) (Figure 8D–E). These consistent results indicated that
DACT1 interferes with the GSK-3b-dependent phosphorylation of
b-catenin by the destruction complex, and DACT1 affects b-
catenin stability by interacting with b-catenin.
DACT1 affects the subcellular localized b-catenin through
inhibiting GSK-3b activity
b-catenin is known to accumulate in the nucleus [29] and its
levels are speculated to increase at the membrane lamellipodia,
membrane adherens junctions and membrane ruffles [30,31] in
response to Wnt signaling or the drug-mediated inhibition of GSK-
3b activity. Moreover, based on our findings, we speculated that
DACT1 inhibits GSK-3b. Some factors that inhibit GSK-3b via the
phosphorylation of Ser9 have been reported [32,33]. We observed
the protein expression levels of GSK-3b with phosphorylated Ser9
in HCT116 cells (with or without DACT1 silencing). The results
showed that the levels of phosphorylated GSK-3b at Ser9 were
significantly increased in HCT116 cells that expressed control
siRNA (Figure 9A and B). To confirm that DACT1 regulated the
localization pattern of b-catenin through inhibiting GSK-3b,w e
tested the effect of GSK-3b inhibition on HCT116 cells that
expressed either the control siRNA or the DACT1 siRNA. We
observed a clear and significant enhancement in cells that displayed
membrane-associated b-catenin staining after they were treated
with 40 mM LiC1 for 1 h (Figure 9C and D). We further tested the
expression of activated b-catenin in SW480 cells. The results
revealed the increased accumulation of nonphosphorylated b-
catenin in cytoplasm and particularly in the nuclei of SW480 cells
that overexpressed DACT1 (Figure 9E and F). All of these results
support the conclusion that DACT1 affects the subcellular
localization of b-catenin through the inhibition of GSK-3b activity.
Figure 7. Correlation between DACT1 levels and membrane-associated b-catenin expression in colon cell lines and colon cancer
tissue. (A) Semiquantitative RT-PCR analysis of DACT1 expression in HCT116, HT29 and SW480 cells. GAPDH was used as the control. (B)
Immunofluorescence analysis of DACT1 and b-catenin expression in HCT116, HT29 and SW480 cells. Original magnification, 406. (C, D) HE staining of
samples of normal human colon mucosa (N) and adenocarcinoma (T) tissues by an anti-b-catenin antibody. Original magnification, 406. (E, F)
immunofluorescence (IF) staining of samples of normal human colon mucosa (N) and adenocarcinoma (T) tissues by an anti-b-catenin antibody.
Original magnification, 406. (G, H) Immunohistochemical (IHC) staining of samples of normal human colon mucosa (N) and adenocarcinoma (T)
tissues by an anti-b-catenin antibody. Original magnification, 406.
doi:10.1371/journal.pone.0034004.g007
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e34004Figure 8. DACT1 interacts with b-catenin and components of the b-Catenin destruction complex to stabilize b-catenin. (A) Western blot
assays in HCT116 cells were performed to determine b-catenin stability. (B) Immunofluorescence assays in HCT116 cells were performed to determine
b-catenin stability. (C) Cell lysates from SW480 cells transfected with GFP-DACT1 were subjected to immunoprecipitation (IP) with anti-axin, anti-GSK-
3b, or anti-b-catenin antibodies. Immunocomplexes were resolved by SDS-PAGE and subjected to Western blot analyses with an anti-GFP antibody.
Blotting with an anti-GAPDH antibody showed equal loading. (D) Subcellular co-localization of endogenous DACT1 and b-catenin, DACT1 and GSk-3b
in HT29 cells. (E) Cell lysates from HT29 cells were subjected to immunoprecipitation (IP) with an anti-DACT1 antibody. Immunocomplexes were
resolved by SDS-PAGE and subjected to Western blot analyses with anti-GSK-3b, or anti-b-catenin antibodies. Blotting with an anti-GAPDH antibody
showed equal loading.
doi:10.1371/journal.pone.0034004.g008
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e34004Figure 9. DACT1 affects the subcellular localization of b-catenin through interacting with GSK-3b. (A) Photomicrographs of control siRNA
and DACT1 siRNA expressing HCT116 cells immunostained with an anti-phospho-GSK-3b(Ser9) antibody (red). Silencing of DACT1 in HCT116 cells
decreases levels of phospho-GSK-3b(Ser9). (B) Representative Western blots of HCT116 cells expressing control siRNA and DACT1 siRNA. Silencing of
DACT1 in HCT116 cells decreases levels of phospho-GSK-3b(Ser9). GAPDH was used as the loading control. (C) HCT116 cells expressing control siRNA
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Increased expression of DACT1 has oncogenic functions
in colon cancer
Our studies have shown that DACT1 is overexpressed in human
colonic adenocarcinomas. This result is consistent with previous
observation that DACT1 was upregulated in invasive breast tumors
[34]. Our studies have also revealed that b-catenin and Dvl-2 are
upregulated along with DACT1, and demonstrate that there is a
trend toward poor survival in patients with tumors that have
higher scores for DACT1 expression in colon adenocarcinomas
[35]. These results suggest that the higher expression of DACT1
may have oncogenic functions in colon cancer. However, DACT1
has also been reported to be downregulated in hepatocellular
carcinoma [18] and lung cancer [19], which suggests that the
function of DACT1 may be dependent on cellular context. Here,
our observations show that the expression of DACT1 enhances
cellular proliferation and promotes tumor growth and metastasis
in the SW480, HCT116, LoVo and HT29 cell lines with or
without APC or b-catenin mutations.
DACT1 upregulates b-catenin levels in colon cancer cells
Xenopus Dpr, the ortholog of DACT1, was found to be a
negative regulator in both Dvl-mediated canonical and noncano-
nical Wnt pathway by Cheyette et al. in 2002 [16]. Concurrently,
Gloy et al. demonstrated that Fordo, another ortholog of DACT1
promotes Wnt signaling in axis formation and in eye and neural
development in Xenopus embryos [36]. To date, the function of
DACT proteins in the regulation of signaling pathways remains
ambiguous, but it is very clear that DACT1 not only regulates
embryonic development but may have an important role in
tumorigenesis. Indeed, one study demonstrated that DACT1 was
downregulated in hepatocarcinoma, and this downregulation was
associated with the methylation of its promoter-associated CpG
island and significantly correlated with the cytoplasmic accumu-
lation of b-catenin [18]. However, Jiang et al. reported that the
expression of DACT1 did not differ significantly between human
colorectal tumors and control tissues, and the DACT1 promoter
was partially methylated [37]. DACT1 expression in lung cancer
was downregulated [19].
We found that DACT1 upregulated b-catenin in colon cancer
cell lines. The higher expression of DACT1 not only increased the
nuclear and cytoplasmic fractions of b-catenin, but also increased
its membrane-associated fraction. In mammals, b-catenin is
originally identified as a component associated with cadherins,
which are Ca2+-dependent cell-cell adhesion molecules [38].
Besides its function in the cadherin complex, b-catenin has an
essential role in the Wnt signaling pathway [39,40,41]. Our results
showed that the E-cadherin expression pattern in colon cancer
cells was unaltered by DACT1 siRNA or DACT1 overexpression.
These results suggest that DACT1 affects the level of b-catenin
through the Wnt signaling pathway. Cyclin D1 and c-Myc are
Wnt target genes. They can regulate the cell cycle and promote
cell proliferation. We found that increased level of DACT1 not only
led to higher levels of total b-catenin and activated b-catenin, but
increased the expression of the b-catenin/TCF target genes, cyclin
D1 and c-Myc. Further studies showed that DACT1 promoted the
proliferation of colon cancer cells by facilitating their transition
from the G1 to the S phase of the cell cycle. The overexpression of
DACT1 in the SW480 cell line resulted in an increase in the
population of cells in the G0/G1 phases. While the expression of
DACT1 in cells with a DACT1 knockdown resulted in an increase
in the population of cells in the S+G2/M phases. Those results are
consistent with the results that DACT1 enhances cellular
proliferation in vitro and colon tumorigenesis in vivo.
The mechanisms of DACT1-induced upregulation of b-
catenin in colon cancer cells
The stability of b-catenin is known to be properly regulated by
the multiprotein complex containing axin, GSK-3b, and APC. In
the absence of an activating Wnt signal, mediated via Wnt binding
to the Frizzled/LRP5/6 coreceptor complex, cytoplasmic b-
catenin is destabilized by the multiprotein complex. Axin acts as
the scaffold of this complex and interacts with the other
components, b-catenin, APC, and GSK-3b. The interaction of
GSK-3b with axin in the complex facilitates efficient phosphor-
ylation of b-catenin by GSK-3b. Phosphorylated b-catenin is then
ubiquitinated, leading to its rapid proteasomal degradation. We
found that DACT1 binds to axin and GSK-3b in colon cancer
cells. The results support the fact that DACT1 interacts with the
destruction complex to prevent the phosphorylation and subse-
quent ubiquitination of b-catenin. We also found that DACT1
interacted with b-catenin in the plasma membrane, which
indicated that DACT1 may directly regulate the degradation of
b-catenin, leading to the accumulation of cytoplasmic b-catenin.
However, the mechanisms by which DACT1 regulates this
multiprotein complex and b-catenin are unclear.
DACT1 has been identified as an interacting protein for Dvl and
induces Dvl degradation via a lysosome inhibitor-sensitive and
proteasome inhibitor-insensitive mechanism [42]. Dvl is a central
mediator of Wnt signaling. It is activated by the binding of Wnt
ligands to the Frizzled/low-density lipoprotein receptor-related
protein (LRP) coreceptor at the cell surface. Activated Dvl binds to
the axin/GSK-3b complex and inhibits the GSK-3b-induced
degradation of b-catenin, therefore activating the expression of
target genes via the b-catenin-T-cell factor-lymphoid enhancer
factor complex [4,15]. Our data showed that DACT1 could
downregulate the expression of Dvl-2 (Figure S4), whereas the
expression of Dvl-1 and Dvl-3 was not been affected by DACT1
(Figure S5). The results suggest that DACT1 upregulates b-catenin
level in colon cancer cells through direct regulation of the
multiprotein complex and b-catenin. It is not clear whether
DACT1 regulates the phosphorylation of Dvl-2.
DACT1 mediated the subcellular localization of b-catenin
b-catenin can be found in three cell compartments: the plasma
membrane, the cytoplasm and the nucleus. The soluble cytoplas-
and DACT1 siRNA were treated for 1 h with GSK-3b inhibitory drugs (40 mM LiCl). Cells were stained and analyzed by microscopy to detect the
expression of b-catenin. LiCl treatment of HCT116 cells increases the levels of b-catenin at the plasma membrane. (D) Representative Western blots of
LiCl-treated HCT116 cells, which express either control siRNA or DACT1 siRNA. LiCl treatment of HCT116 cells increases levels of b-catenin at the
plasma membrane. KDEL was used as a loading control. 1: HCT116 cells expressing control siRNA that had been treated with 40 mM LiCl for 1 h. 2:
HCT116 cells expressing control siRNA that had not been treated with LiCl. 3: HCT116 cells expressing DACT1 siRNA that were treated by 40 mM LiCl
for 1 h; 4: HCT116 cells expressing DACT1 siRNA that had not been treated with LiCl. (E) Photomicrographs of control siRNA and DACT1 siRNA
expressing HCT116 cells immunostained with an anti-phospho-GSK-3b(Ser9) antibody (red). Silencing of DACT1 in HCT116 cells decreases levels of
phospho-GSK-3b(Ser9). (F) Representative Western blots of HCT116 cells expressing control siRNA and DACT1 siRNA. Silencing of DACT1 in HCT116
cells decreases levels of phospho-GSK-3b(Ser9). GAPDH was used as a loading control.
doi:10.1371/journal.pone.0034004.g009
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Wnt signal, this results in nuclear localization. Nuclear b-catenin is
a cofactor for a wide variety of transcription factors that regulate
the expression of many genes involved in cell growth. At the
membrane, b-catenin plays a pivotal role in cell-cell adhesion,
linking the cytoplasmic domain of E-cadherin to a-catenin. The
deregulation of b-catenin or E-cadherin leads to the loss of cell-cell
adhesion [43]. We found that increased levels of DACT1 led to
higher levels of membrane-associated b-catenin, but the E-
cadherin expression pattern in colon cancer cells was unaltered
by DACT1 siRNA or the overexpression of DACT1. We also found
DACT1 enhanced anchorage independence, as well as the
migratory and invasive potential of colon cancer cell lines. These
results are consistent with the above theories. In addition, our data
showed that the DACT1 expression level and membrane-
associated b-catenin expression level were positively correlated in
colon cancer cell lines and primary colon cancers. These results
are consistent with our previous report that showed b-catenin was
upregulated and is associated with DACT1 levels. This demon-
strates that there is a trend toward poor survival in patients with
tumors that have higher scores for DACT1 expression in colon
adenocarcinomas [35].
Mechanisms by which DACT1 mediates the subcellular
localization of b-catenin
Some reports have shown that b-catenin can shuttle in a
bidirectional manner between the nucleus and cytoplasm, or
between the nucleus and the cell membrane [44,45,46]. This is
necessary to enable the cell to respond quickly to fluctuations in
extracellular stimuli that require it to switch between nuclear
transactivation and membrane cell adhesion or cell migration
activities [30]. Previous studies have shown that the inhibition of
GSK-3b promoted the accumulation of b-catenin in the nucleus
[29] and at the plasma membrane [30,31], which our data
confirmed. In our studies, increased level of phosphorylated GSK-
3b at Ser9 were present in HCT116 cells that expressed control
siRNA, which led to the higher expression of b-catenin in the
nucleus, cytoplasm and at the plasma membrane. We further
found that DACT1 interacted with GSK-3b. This result supports
the finding that DACT1 regulates the subcellular location of b-
catenin through inhibiting the activity of GSK-3b. Reports have
shown that Dvl can inhibit the activity of GSK-3b [47,48]. Our
studies showed that DACT1 could downregulate the expression of
Dvl-2, whereas the expression of Dvl-1 and Dvl-3 was not been
affected by DACT1 (Figure S4 and S5). These data further show
that b-catenin accumulates in the nucleus and at the plasma
membrane as a result of the inhibition of GSK-3b by DACT1.
The model for the mechanism by which DACT1 promotes
the oncogenesis of colon cancer cells
The data in the present study support the following model for
the mechanism by which DACT1 promotes the oncogenesis of
colon cancer cells (Figure 10). In unstimulated, normal colon cells
that lack DACT1, GSK-3b is present in the cytoplasm and forms
the b-catenin destruction complex with axin and APC. This allows
the destruction complex to phosphorylate b-catenin and target it
Figure 10. Putative model of how DACT1 mediates the activation of b-catenin signaling in colon cancer cells. Left: In unstimulated
normal colon cells lacking DACT1, the axin/GSK-3b/APC phosphorylate b-catenin and target it for ubiquitin-mediated degradation. Right: In colon
cancer cells that express high levels of DACT1, DACT1 binds to b-catenin. DACT1 then binds and inhibits GSK-3b, which inhibits the function of the
destruction complex, resulting in the release of b-catenin. This leads to increased nuclear and cytoplasmic fractions of b-catenin, and increased levels
of membrane-bound b-catenin. Subsequently, the migration and invasion capacities of the colon cancer cells are enhanced and downstream target
genes are activated.
doi:10.1371/journal.pone.0034004.g010
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express high levels of DACT1, we propose that DACT1 interacts
with b-catenin, after which DACT1 binds to and inhibits GSK-3b,
which results in the release of b-catenin from the destruction
complex, increased intracellular b-catenin levels, and its subse-
quent accumulation in the nucleus. This would lead to the
activation of downstream b-catenin/TCF-regulated target genes,
and at the membrane, regulation of the adhesion or migration
properties of the cell. These studies define a functional role of
DACT1 in human tumorigenesis and, besides highlighting DACT1
as a potential therapeutic target in colon cancer, define a
mechanism for the regulation of b-catenin in cancer.
Materials and Methods
Tissue specimens and cell lines
Colon carcinoma tissues were obtained from the Peking
University Third Hospital, China. Samples were frozen in liquid
nitrogen immediately after surgical removal and maintained at
80uC until use. All human tissue was collected using protocols that
were approved by the Ethics Committee of the Peking University
Health Science Center. Patients diagnosed with colon adenocar-
cinoma were included if they had no family history of CRC or
secondary malignancy, and had not received radiotherapy or
chemotherapy before surgery. The human colon cancer cell lines
were obtained from the cell resources centers of the Shanghai
Institutes for Biological Sciences (Shanghai, China).
Plasmid construction
The cDNA of human DACT1 extracted from 293T cells was
subcloned into the pEGFP-N1 expression vector (Invitrogen,
Carlsbad, CA, USA). The sequences were verified by DNA
sequencing. All of the control siRNAs and DACT1 siRNAs
constructs were kindly provided by Dr. Yeguang Chen (Tsinghua
University, China).
Quantitative real-time PCR and semi-reverse
transcription-PCR
Total RNA from the human tissues and cell lines were isolated
using TRIzol reagent (Invitrogen) according to the manufacturer’s
protocol. The cDNA of cell lines were synthesized using a High-
Capacity cDNA Archive Kit (Invitrogen). Primer sequences for
DACT1 were as follows: sense, 59- CACAAGCGAACTGAC-
TACCG-39; antisense, 59-GTAATTGCTCTGCTCGTCCT-39.
The primers for GAPDH were: sense, 59 –A CAG T C
CATGCCATCACTGCC-39; antisense, 59-GCCTGCTTCAC-
CACCTTCTTG-39. Twenty-five cycles were used. The condi-
tions for hot-start PCR were as follows: 95uC for 10 min, followed
by amplification at 95uC for 1 min, 58uC for 30 s and 62uC for
30 s for DACT1 and GAPDH, respectively, and 72uC for 30 s,
with a final extension at 72uC for 10 min.
The cDNA of human tissues served as a template in
quantitative real-time PCR utilizing TaqMan Gene Expression
Master Mix and TaqMan Gene Expression assay probes for
DACT1 (Hs00420410_m1), or GAPDH (Hs03929097_g1; Applied
Biosystems, Foster City, CA, USA) and an ABI 7500 Fast
Sequence Detection System. All reactions were performed in
triplicate. The DACT1 mRNA expression of different group
specimens was normalized to endogenous GAPDH. The relative
DACT1 mRNA levels were presented as unit values of
2
2DCt=2
2(Ct (GAPDH)2Ct (DACT1)), where Ct is the threshold
cycle value defined as the fractional cycle number at which the
target fluorescent signal passes a fixed threshold above the
baseline.
Immunoblot analysis
After the frozen tissues were homogenized in liquid nitrogen and
the cultured cells were digested by Trypsin/EDTA Solution
(pH 7.4; 0.025% trypsin, 0.5 mM EDTA, 1 mM sodium pyruvate
and 10 mM HEPES), whole-cell lysates were prepared by
incubating cells in ice-cold lysis buffer (50 mM Tris-HCl
[pH 8.0], 150 mM NaCl, 1% Triton X-100 and 100 mg/ml of
phenylmethylsulfonyl fluoride) for 30 min. The tissue samples and
cells were sonicated for 8 s and then placed on ice for 5 min. The
lysates were then centrifuged at 12,000 g for 20 min at 4uC. The
supernatant was collected, aliquotted and frozen at 280uC before
use. Proteinconcentrationsweredetermined witha proteinassay kit
(Bio-Rad Laboratories, Hercules, CA, USA) according to the
protocol of the manufacturer. Equal amounts of protein were
resolved by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to PVDF membranes
(Millipore, Bedford, MA, USA). The antibodies used in these
experiments included DACT1 (1:8,000; Abcam, Cambridge, UK),
b-catenin (1:4,000; Cell Signaling Technology, Beverly, MA, USA),
c-Myc, cyclin D1, CDK4, GSK-3b, Axin1, (all diluted to 1:2,000;
Cell Signaling Technology), active-b-Catenin (1:2,000; Millipore).
After analysis, the blots were stripped, washed and re-probed with
an antibody against GAPDH (Sigma, St. Louis, MO, USA), which
served as the loading control. Images were visualized with an
enhanced chemiluminescence (ECL) detection system (Amersham
Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK).
Cell culture
All of the cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (Invitrogen),
nonessential amino acids, L-glutamine, and penicillin/streptomy-
cin in an atmosphere that contained 5% CO2 at 37uC.
Creation of stable cell lines
SW480 cells were stably transfected with pEGFP-N1-DACT1
and pEGFP-N1 empty vectors so that they would stably
overexpress DACT1. The selection for G418 resistance was
initiated 72 h after transfection by the addition of 300 mg/ml of
G418 (Invitrogen) to the culture medium. The selection media was
changed every 3–4 days for several weeks, and clones of resistant
G418 cells were isolated and expanded for further characteriza-
tion. DACT1 expression in stably transfected cells was verified by
Western blotting, as described above.
To silence DACT1 expression, HCT116 and LoVo and HT29
cells were stably transfected with DACT1 siRNA and control siRNA
expression vectors. Selection for puromycin resistance was initiated
72 h after transfection by the addition of 5 mg/ml puromycin
(Invitrogen) to the culture medium. The selection media was
changed every 3–4 days for several weeks, and clones of puromycin-
resistant cells were isolated and expanded for further characteriza-
tion. The silencing of DACT1 expression in stably transfected cells
was verified by Western blotting, as described above.
Proliferation assay
Cells were seeded in 24-well plates at 1610
4 cells per well in a
volume of 1 ml of supplemented medium. The supplemented
medium was changed every day. Cell numbers were counted every
24 h with the use of a NucleoCounter cell counter (Chemomete,
Denmark).
Soft agar colony assay
Cell suspensions (1,000 cells) were prepared using 0.6% Noble
agarose (Becton Dickinson) and overlaid onto a 24-well plate that
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Once the top layer had solidified, 1 ml of medium was placed on
the top of the cell layer. After treatment, plates were incubated for
3 weeks and colonies were counted with the assistance of a
stereomicroscope.
Transwell migration assay
For transwell migration assays, 5610
4 cells were plated into the
top chamber on a noncoated membrane (24-well insert; pore size,
8 mm; Corning Costar, NY, USA); cells were then allowed to
migrate toward the medium that contained serum in the lower
chamber. Cells were fixed with methanol after 24 h of incubation
and stained with 0.1% crystal violet (2 mg/mL; Sigma-Aldrich).
The number of cells that invaded through the membrane was
counted under a light microscope (206, three random fields per
well).
Transwell invasion assay
For the invasion assay, 5610
4 cells were plated in the top
chamber onto the Matrigel-coated membrane (24-well insert; pore
size, 8 mm; Millipore). Cells were plated in medium without
serum, and medium supplemented with serum was used as a
chemoattractant in the lower chamber. The cells were incubated
for 24 h and cells that did invade through the pores were removed
with a cotton swab. Cells on the lower surface of the membrane
were fixed with methanol and stained with crystal violet. The
number of cells invading through the membrane was counted
under light microscopy (206, three random fields per well).
Flow cytometry analysis
After all of the cells were synchronized to the G0/G1 phases by
serum starvation, the cells were cultured for 72 h. Then, the cells
were washed twice with ice-cold phosphate buffered saline (PBS),
harvested, fixed with ice-cold PBS in 70% ethanol, and stored at
220uC for 30 min. After fixation, the cells were incubated with
RNase A (0.1 mg/ml, Sigma-Aldrich) at 37uC for 30 min, stained
with propidium iodide (50 mg/ml, Sigma-Aldrich) for 30 min on
ice in the dark and analyzed for DNA content using a flow
cytometer (FACSCalibur; BD Biosciences). Data were collected in
list mode for at least on 10,000 events and analyzed using Mod Fit
2.0 software.
Immunohistochemical analysis
The paraffin-embedded colon tissue sections (4-mm thick) were
cut, deparaffinized, and subjected to a heat-induced epitope
retrieval step. Endogenous peroxidase activity was blocked with
1% (v/v) hydrogen peroxide in distilled water. To block
nonspecific binding, the sections were incubated with 2% (g/v)
BSA for 60 min at room temperature. Subsequently, samples were
incubated with a rabbit polyclonal b-catenin antibody (Cell
Signaling Technology), diluted to 1:200 in PBS for spending the
night at 4uC. For negative controls, sections were incubated with
PBS without the primary antibody. For detection, specimens were
sequentially incubated with biotinylated mouse anti-rabbit immu-
noglobulin G (IgG) and streptavidin-horseradish peroxidase. b-
catenin expression levels in the stained sections were evaluated by
an experienced pathologist.
Immunofluorescence microscopy
The OCT (optimal cutting temperature)-embedded colon tissue
sections (4-mm thick) were cut. Cells were grown on a confocal dish
(1610
5/mL) and allowed to grow for 48 h. The sections and cells
were then fixed for 10 min in ice-cold 4% paraformaldehyde with
0.2% Triton-100. The sections and cells were washed in PBS and
incubated for 1 h in TBS containing 5% BSA. Sections and cells
were incubated overnight at 4uCw i t hab-catenin antibody (1:200
dilution), E-cadherin antibody (1:200 dilution), or phospho-GSK-
3b(Ser9) (1:100; Cell Signaling Technology), active b-catenin
antibody (1:200 dilution; Millipore). For the double-immunola-
belling experiments, the primary antibodies against GFP (anti-
mouse; 1:50), b-catenin antibody (anti-rabbit; 1:200); axin1
antibody (anti-rabbit; 1:200), GSK-3b (anti-rabbit; 1:200) and
DACT1 antibody (anti-rabbit; 1:200), b-catenin antibody (anti-
mouse; 1:200) or GSK-3b (anti-mouse; 1:200; Santa Cruz) were
incubated simultaneously overnight at 4uC. Sections and cells
grown on the confocal dish were rinsed at least three times for
5 min in PBS, and were then simultaneously incubated with the
secondary antibody fluorescein (FITC)-conjugated anti-mouse
IgG (Jackson, West Grove, PA, USA), or Dyelight594-conjugated
anti-rabbit IgG (Jackson) at a 1:1,000 dilution for 1 h at room
temperature. Sections and cells were then counterstained with
49,6-diamidino-2-phenylindole (DAPI) and mounted with Vecta-
shield (Vector Laboratories, Burlingame, CA). Immunofluores-
cence was visualized using a laser confocal scanning microscope
(LSM 510 Meta).
Nuclear and membrane fractionation
Nuclear and cytoplasmic proteins were extracted using a NE-
PERN Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce,
Rockford, IL, USA). Membrane proteins were extracted using a
Mem-PER Eukaryotic Membrane Protein Extraction Kit (Pierce),
according to the instructions of the manufacturer.
Immunoprecipitation
The cells were lysed with 1 ml of lysis buffer (20 mM Tris-HCl,
pH 7.4, 2 mM EDTA, 25 mM NaF, 1% Triton X-100) plus
protease inhibitors (Sigma) for 30 min at 4uC. After 12,000 g
centrifugation for 15 min, the lysates were immunoprecipitated
with specific antibody and protein A-Sepharose (Zymed Labora-
tories Inc., San Francisco, CA, USA) for 3 h at 4uC. Thereafter,
the precipitants were washed three times with washing buffer
(50 mM Tris-HCl, pH 8.0, 15 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, and 0.1% SDS). The immune
complexes were then eluted with sample buffer containing 1%
SDS for 5 min at 95uC and analyzed by SDS-PAGE.
In vivo tumorigenicity studies
Six- to 8-week-old female nude mice were obtained from the
AnimalCenter ofPekingUniversity Health Science Center (Beijing,
China). Eight animals per group were used in each experiment.
Briefly, 5610
6 HCT116 cells (expressing control siRNA or DACT1
siRNA) in 200 ml PBS were injected into the subcutaneous tissue of
the nude mouse. Tumors were measured weekly using a vernier
caliper, and the tumor volume was calculated according to the
following formula: p/66length6width
2 [21]. Tumors were col-
lected at the time of sacrifice 8 weeks after infection. All studies were
approved by the Animal Care Committee of Peking University
Health Science Center.
Statistical analysis
Data are represented as mean 6 standard error of the mean
(SEM) from at least three independent experiments. The
significance of differences between groups was evaluated by
Student’s t-test or ANOVA. P-values,0.05 were considered to be
significant.
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Figure S1 The effects of DACT1 on cellular proliferation
and b-catenin levels in HCT116 cells. (A) DACT1 expression
in wild-type, control siRNA-transfected, and DACT1 siRNA1-
transfected HCT116 cells. (B) Growth curve assays in DACT1
siRNA1-transfected HCT116 cells (mean 6 SEM; n=3, *p,0.05
versus wild-type cells). (C) Soft agar assay in siRNA1-transfected
HCT116 cells after 14 days of incubation. (D) Photomicrographs
of control siRNA and DACT1 siRNA1 in HCT116 cells
immunostained with an anti-b-catenin antibody (red).
(TIF)
Figure S2 Representative Western blots showing CDK4
expression levels in colon cancer cells. ‘‘+’’ represents the
overexpression of DACT1 in SW480 cells and control siRNA in
HCT116, LoVo and HT29 cells. ‘‘2’’ represents empty vector in
SW480 cells and DACT1 siRNA in HCT116, LoVo and HT29
cells.
(TIF)
Figure S3 A representative photomicrograph immuno-
stained with anti-E-cadherin antibody (green) in colon
cancer cells.
(TIF)
Figure S4 A representative photomicrograph immuno-
stained with anti-Dvl-2 antibody (red) in colon cancer
cells.
(TIF)
Figure S5 Representative Western blots showing Dvl-1
and Dvl-3 expression levels in colon cancer cells. ‘‘+’’
represents the overexpression DACT1 in SW480 cells and control
siRNA in HCT116, LoVo and HT29 cells. ‘‘2’’ represents empty
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